Review



compounds diabzi  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    MedChemExpress compounds diabzi
    Compounds Diabzi, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 38 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/compounds diabzi/product/MedChemExpress
    Average 93 stars, based on 38 article reviews
    compounds diabzi - by Bioz Stars, 2026-05
    93/100 stars

    Images



    Similar Products

    95
    InvivoGen diabzi compound 3
    Diabzi Compound 3, supplied by InvivoGen, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/diabzi compound 3/product/InvivoGen
    Average 95 stars, based on 1 article reviews
    diabzi compound 3 - by Bioz Stars, 2026-05
    95/100 stars
      Buy from Supplier

    93
    MedChemExpress compounds diabzi
    Compounds Diabzi, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/compounds diabzi/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    compounds diabzi - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    96
    Selleck Chemicals sting agonist diabzi
    a-g, Therapeutic efficacy of i-Bind NPs loaded with <t>diABZI</t> and other control formulations (n=7 biologically independent animals). a, Schematic illustration of the treatment schedule. Created in BioRender. Zhao, Z. (2025) https://BioRender.com/ut0otug . b, Representative bioluminescence images of lung metastasis progression at different time points. c, Lung metastasis progression of individual mouse indicated by bioluminescence intensity. d, Overall lung metastasis progression curve. e, Lung metastasis tumor burden on day 22 indicated by bioluminescence intensity. f, Representative images of lungs following different treatments on day 23. g, Number of surface metastatic nodules on the lungs on day 23. h-p, Changes of the lung immune cell profiles following different treatments on day 23 (n=6 biologically independent animals). h-i, Number of total CD45 + immune cells (h) and various immune cell subtypes (i) in the lungs. j, Number of CD103 + cDC1s and CD11b + cDC2s in the lungs. k, Relative ratio of cDC1s to cDC2s. l, Expression level of DC activation marker CD86 on cDC1s (indicated by Mean fluorescence intensity, MFI). m, Number of CD4 and CD8 T cells in the lungs. n, Relative ratio of CD8 to CD4 T cells in the lungs. o, Relative number of IFN-γ-expressing CD8 T cells of total CD3 T cells in the lungs. p, Relative number of Tregs of total CD3 T cells in the lungs. Data in (e, g-h, j-p) are presented as mean ± SEM. For (e, g-i, j-p) , statistical analysis was conducted by one-way ANOVA followed by Dunnett’s test: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. For ( i ), black, pink, and green asterisks indicate comparisons between the i-Bind diABZI group with saline, PLGA diABZI, and free diABZI groups, respectively.
    Sting Agonist Diabzi, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sting agonist diabzi/product/Selleck Chemicals
    Average 96 stars, based on 1 article reviews
    sting agonist diabzi - by Bioz Stars, 2026-05
    96/100 stars
      Buy from Supplier

    95
    InvivoGen diabzi compound 3 tlrl diabzi
    a-g, Therapeutic efficacy of i-Bind NPs loaded with <t>diABZI</t> and other control formulations (n=7 biologically independent animals). a, Schematic illustration of the treatment schedule. Created in BioRender. Zhao, Z. (2025) https://BioRender.com/ut0otug . b, Representative bioluminescence images of lung metastasis progression at different time points. c, Lung metastasis progression of individual mouse indicated by bioluminescence intensity. d, Overall lung metastasis progression curve. e, Lung metastasis tumor burden on day 22 indicated by bioluminescence intensity. f, Representative images of lungs following different treatments on day 23. g, Number of surface metastatic nodules on the lungs on day 23. h-p, Changes of the lung immune cell profiles following different treatments on day 23 (n=6 biologically independent animals). h-i, Number of total CD45 + immune cells (h) and various immune cell subtypes (i) in the lungs. j, Number of CD103 + cDC1s and CD11b + cDC2s in the lungs. k, Relative ratio of cDC1s to cDC2s. l, Expression level of DC activation marker CD86 on cDC1s (indicated by Mean fluorescence intensity, MFI). m, Number of CD4 and CD8 T cells in the lungs. n, Relative ratio of CD8 to CD4 T cells in the lungs. o, Relative number of IFN-γ-expressing CD8 T cells of total CD3 T cells in the lungs. p, Relative number of Tregs of total CD3 T cells in the lungs. Data in (e, g-h, j-p) are presented as mean ± SEM. For (e, g-i, j-p) , statistical analysis was conducted by one-way ANOVA followed by Dunnett’s test: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. For ( i ), black, pink, and green asterisks indicate comparisons between the i-Bind diABZI group with saline, PLGA diABZI, and free diABZI groups, respectively.
    Diabzi Compound 3 Tlrl Diabzi, supplied by InvivoGen, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/diabzi compound 3 tlrl diabzi/product/InvivoGen
    Average 95 stars, based on 1 article reviews
    diabzi compound 3 tlrl diabzi - by Bioz Stars, 2026-05
    95/100 stars
      Buy from Supplier

    96
    Selleck Chemicals commerical diabzi molecule compound 3
    a-g, Therapeutic efficacy of i-Bind NPs loaded with <t>diABZI</t> and other control formulations (n=7 biologically independent animals). a, Schematic illustration of the treatment schedule. Created in BioRender. Zhao, Z. (2025) https://BioRender.com/ut0otug . b, Representative bioluminescence images of lung metastasis progression at different time points. c, Lung metastasis progression of individual mouse indicated by bioluminescence intensity. d, Overall lung metastasis progression curve. e, Lung metastasis tumor burden on day 22 indicated by bioluminescence intensity. f, Representative images of lungs following different treatments on day 23. g, Number of surface metastatic nodules on the lungs on day 23. h-p, Changes of the lung immune cell profiles following different treatments on day 23 (n=6 biologically independent animals). h-i, Number of total CD45 + immune cells (h) and various immune cell subtypes (i) in the lungs. j, Number of CD103 + cDC1s and CD11b + cDC2s in the lungs. k, Relative ratio of cDC1s to cDC2s. l, Expression level of DC activation marker CD86 on cDC1s (indicated by Mean fluorescence intensity, MFI). m, Number of CD4 and CD8 T cells in the lungs. n, Relative ratio of CD8 to CD4 T cells in the lungs. o, Relative number of IFN-γ-expressing CD8 T cells of total CD3 T cells in the lungs. p, Relative number of Tregs of total CD3 T cells in the lungs. Data in (e, g-h, j-p) are presented as mean ± SEM. For (e, g-i, j-p) , statistical analysis was conducted by one-way ANOVA followed by Dunnett’s test: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. For ( i ), black, pink, and green asterisks indicate comparisons between the i-Bind diABZI group with saline, PLGA diABZI, and free diABZI groups, respectively.
    Commerical Diabzi Molecule Compound 3, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/commerical diabzi molecule compound 3/product/Selleck Chemicals
    Average 96 stars, based on 1 article reviews
    commerical diabzi molecule compound 3 - by Bioz Stars, 2026-05
    96/100 stars
      Buy from Supplier

    Image Search Results


    a-g, Therapeutic efficacy of i-Bind NPs loaded with diABZI and other control formulations (n=7 biologically independent animals). a, Schematic illustration of the treatment schedule. Created in BioRender. Zhao, Z. (2025) https://BioRender.com/ut0otug . b, Representative bioluminescence images of lung metastasis progression at different time points. c, Lung metastasis progression of individual mouse indicated by bioluminescence intensity. d, Overall lung metastasis progression curve. e, Lung metastasis tumor burden on day 22 indicated by bioluminescence intensity. f, Representative images of lungs following different treatments on day 23. g, Number of surface metastatic nodules on the lungs on day 23. h-p, Changes of the lung immune cell profiles following different treatments on day 23 (n=6 biologically independent animals). h-i, Number of total CD45 + immune cells (h) and various immune cell subtypes (i) in the lungs. j, Number of CD103 + cDC1s and CD11b + cDC2s in the lungs. k, Relative ratio of cDC1s to cDC2s. l, Expression level of DC activation marker CD86 on cDC1s (indicated by Mean fluorescence intensity, MFI). m, Number of CD4 and CD8 T cells in the lungs. n, Relative ratio of CD8 to CD4 T cells in the lungs. o, Relative number of IFN-γ-expressing CD8 T cells of total CD3 T cells in the lungs. p, Relative number of Tregs of total CD3 T cells in the lungs. Data in (e, g-h, j-p) are presented as mean ± SEM. For (e, g-i, j-p) , statistical analysis was conducted by one-way ANOVA followed by Dunnett’s test: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. For ( i ), black, pink, and green asterisks indicate comparisons between the i-Bind diABZI group with saline, PLGA diABZI, and free diABZI groups, respectively.

    Journal: bioRxiv

    Article Title: Lung-Selective Immune Reprogramming via In Situ Red Blood Cell Hitchhiking Nanoparticles

    doi: 10.64898/2026.02.27.708550

    Figure Lengend Snippet: a-g, Therapeutic efficacy of i-Bind NPs loaded with diABZI and other control formulations (n=7 biologically independent animals). a, Schematic illustration of the treatment schedule. Created in BioRender. Zhao, Z. (2025) https://BioRender.com/ut0otug . b, Representative bioluminescence images of lung metastasis progression at different time points. c, Lung metastasis progression of individual mouse indicated by bioluminescence intensity. d, Overall lung metastasis progression curve. e, Lung metastasis tumor burden on day 22 indicated by bioluminescence intensity. f, Representative images of lungs following different treatments on day 23. g, Number of surface metastatic nodules on the lungs on day 23. h-p, Changes of the lung immune cell profiles following different treatments on day 23 (n=6 biologically independent animals). h-i, Number of total CD45 + immune cells (h) and various immune cell subtypes (i) in the lungs. j, Number of CD103 + cDC1s and CD11b + cDC2s in the lungs. k, Relative ratio of cDC1s to cDC2s. l, Expression level of DC activation marker CD86 on cDC1s (indicated by Mean fluorescence intensity, MFI). m, Number of CD4 and CD8 T cells in the lungs. n, Relative ratio of CD8 to CD4 T cells in the lungs. o, Relative number of IFN-γ-expressing CD8 T cells of total CD3 T cells in the lungs. p, Relative number of Tregs of total CD3 T cells in the lungs. Data in (e, g-h, j-p) are presented as mean ± SEM. For (e, g-i, j-p) , statistical analysis was conducted by one-way ANOVA followed by Dunnett’s test: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. For ( i ), black, pink, and green asterisks indicate comparisons between the i-Bind diABZI group with saline, PLGA diABZI, and free diABZI groups, respectively.

    Article Snippet: STING agonist diABZI (Compound 3) was purchased from Selleck Chemicals LLC (Houston, TX).

    Techniques: Drug discovery, Control, Expressing, Activation Assay, Marker, Fluorescence, Saline